Skye Bioscience Inc (SKYE)
3.54
-0.03
(-0.84%)
USD |
NASDAQ |
Oct 04, 16:00
3.55
+0.01
(+0.28%)
After-Hours: 17:28
Skye Bioscience SG&A Expense (TTM): 13.26M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 13.26M |
March 31, 2024 | 10.14M |
December 31, 2023 | 7.852M |
September 30, 2023 | 6.898M |
June 30, 2023 | 5.803M |
March 31, 2023 | 6.388M |
December 31, 2022 | 6.095M |
September 30, 2022 | 5.902M |
June 30, 2022 | 6.253M |
March 31, 2022 | 5.411M |
December 31, 2021 | 4.916M |
September 30, 2021 | 4.517M |
June 30, 2021 | 4.218M |
March 31, 2021 | 4.061M |
December 31, 2020 | 4.345M |
September 30, 2020 | 4.523M |
June 30, 2020 | 4.321M |
March 31, 2020 | 4.612M |
December 31, 2019 | 4.395M |
September 30, 2019 | 4.345M |
June 30, 2019 | 4.333M |
March 31, 2019 | 4.330M |
December 31, 2018 | 4.363M |
September 30, 2018 | 4.201M |
Date | Value |
---|---|
June 30, 2018 | 3.896M |
March 31, 2018 | 3.486M |
December 31, 2017 | 3.548M |
September 30, 2017 | 3.280M |
June 30, 2017 | 3.383M |
March 31, 2017 | 3.735M |
December 31, 2016 | 3.532M |
September 30, 2016 | 3.694M |
June 30, 2016 | 3.662M |
March 31, 2016 | 3.953M |
December 31, 2015 | 3.741M |
September 30, 2015 | 4.598M |
June 30, 2015 | 4.517M |
March 31, 2015 | 3.237M |
December 31, 2014 | 2.411M |
September 30, 2014 | 0.7719M |
July 31, 2014 | 0.1493M |
April 30, 2014 | 0.1553M |
January 31, 2014 | 0.1494M |
October 31, 2013 | 0.1485M |
July 31, 2013 | 0.1142M |
April 30, 2013 | 0.0749M |
January 31, 2013 | 0.0353M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
4.061M
Minimum
Mar 2021
13.26M
Maximum
Jun 2024
5.996M
Average
5.411M
Median
Mar 2022
SG&A Expense (TTM) Benchmarks
Oramed Pharmaceuticals Inc | 7.523M |
Viking Therapeutics Inc | 37.92M |
NovaBay Pharmaceuticals Inc | 11.53M |
Palatin Technologies Inc | 12.27M |
iBio Inc | 11.67M |